2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Xanthine Oxidase

Xanthine Oxidase

XO

Xanthine Oxidase

Related Products

PDF 0.47 MB

Xanthine oxidase (XO), a versatile molybdoflavoprotein, catalyzes the oxidative hydroxylation of purine substrates (hypoxanthine and xanthine) to produce uric acid and subsequent reduction of oxygen at the flavin center with the generation of reactive oxygen species, either superoxide anion radical or hydrogen peroxide.

Xanthine oxidase is an important enzyme of purine catabolism pathway and has been associated directly in pathogenesis of gout and indirectly in many pathological conditions like cancer, diabetes and metabolic syndrome. The selective inhibition of xanthine oxidase may result in a broad spectrum therapeutic use for gout, cancer, inflammation and oxidative damage.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-160424
    DEANO sodium
    DEANO sodium is notric oxide donor. DEANO sodium potentiates the abilitv of hypoxanthine/xanthine oxidase to induce lipid peroxidation as well as DNA single- and double-strand breaks.
    DEANO sodium
  • HY-N0814A
    Phytic acid dodecasodium hydrate
    		Inhibitor ≥98.0%
    Phytic acid (Inositol hexaphosphate) dodecasodium hydrate is a phosphorus storage compound of seeds and cereal grains. Phytic acid dodecasodium hydrate is known as a food inhibitor, which has a strong ability to chelate multivalent metal ions, specially zinc, calcium, iron and as with protein residue. Phytic acid dodecasodium hydrate inhibits the enzymatic superoxide source xanthine oxidase (XO), and has antioxidative, neuroprotective, anti-inflammatory effects.
    Phytic acid dodecasodium hydrate
  • HY-N2472
    Medicagenic acid
    		98.97%
    Medicagenic acid (Castanogenin) is isolated from the roots of Herniaria glabra, exhibits potent fungistatic effects against several plant pathogens and human dermatophytes. Medicagenic acid (Castanogenin) has low enzyme inhibitory activities, the target enzymes are xanthine oxidase, collagenase, elastase, tyrosinase, ChE.
    Medicagenic acid
  • HY-N3220
    Myricetin 3-O-galactoside
    		Inhibitor ≥99.0%
    Myricetin 3-O-galactoside inhibits xanthine oxidase (XO) activity, lipid peroxidation and scavenges the free radical. Myricetin 3-O-galactoside inhibits lipid peroxidation with an IC50 of 160 μg/mL. Antioxidant activity.
    Myricetin 3-O-galactoside
  • HY-139585
    Tigulixostat
    		Inhibitor 99.18%
    Tigulixostat (LC350189) is an orally active non-purine selective xanthine oxidase inhibitor. Tigulixostat has IC50 values of 0.003 µM and 0.073 µM in bovine milk and rat plasma, respectively. Tigulixostat can effectively reduce serum uric acid levels and can be used in the research of gout and hyperuricemia.
    Tigulixostat
  • HY-N8600
    7,8,3′,4′-Tetrahydroxyflavone
    		Inhibitor 99.51%
    7,8,3′,4′-Tetrahydroxyflavone (compound 2) is a potent xanthine oxidase (XOD) inhibitor with an IC50 value of 10.488 µM.
    7,8,3′,4′-Tetrahydroxyflavone
  • HY-W037417
    DAO-IN-1
    		Inhibitor
    DAO-IN-1 is a potent inhibitor of D-amino acid oxidase (DAO) with an IC50 value of 269 nM. DAO is an enzyme responsible for D-serine metabolism, D-serine is a co-agonist of NMDA receptors.
    DAO-IN-1
  • HY-B0219A
    Allopurinol sodium
    		Inhibitor 99.88%
    Allopurinol sodium is a potent and orally active xanthine oxidase inhibitor with an IC50 value of 0.2-50 μM. Allopurinol sodium can be used in the research of hyperuricemia and gout. Allopurinol sodium decreases the expression of HIF-1α and HIF-2α protein. Allopurinol sodium shows anti-depressant and anti-nociception activity. Anti-leishmanial effect.
    Allopurinol sodium
  • HY-N9330
    Broussoflavonol F
    		Inhibitor 98.11%
    Broussoflavonol F possess xanthine oxidase inhibitory activity.
    Broussoflavonol F
  • HY-153968
    URAT1&XO inhibitor 1
    		Inhibitor 99.96%
    URAT1&XO inhibitor 1 (compound 29) is a dual inhibitor of both URAT1 (IC50=~10 μM) and Xanthine Oxidase (IC50=1.01 μM). URAT1&XO inhibitor 1 results hypouricemic effect in potassium oxonate-induced hyperuricemia rat model. URAT1&XO inhibitor 1 is used for hyperuricemia research.
    URAT1&XO inhibitor 1
  • HY-B0219S
    Allopurinol-d2
    		Inhibitor 98.36%
    Allopurinol-d2 is deuterium labeled Allopurinol. Allopurinol is a potent xanthine oxidase inhibitor (IC50 values of 0.2 to 50 μM). Allopurinol can be used for the research of hyperuricemia and gout. Antileishmanial effect[1][2].
    Allopurinol-d<sub>2</sub>
  • HY-14268S
    Febuxostat-d9
    		Inhibitor 98.70%
    Febuxostat-d9 is deuterium labeled Febuxostat, which is a selective xanthine oxidase inhibitor with a Ki of 0.6 nM.
    Febuxostat-d<sub>9</sub>
  • HY-131268
    O-Desisobutyl-O-n-propyl Febuxostat
    		Inhibitor
    O-Desisobutyl-O-n-propyl Febuxostat, extracted from the patent CN 103467412, is an xanthine oxidase inhibitor.
    O-Desisobutyl-O-n-propyl Febuxostat
  • HY-153972
    URAT1&XO inhibitor 2
    		Inhibitor 98.69%
    URAT1&XO inhibitor 2 (Compound BDEO) is a dual inhibitor of xanthine oxidase and URAT1, with IC50 of 3.3 μM for xanthine oxidase. URAT1&XO inhibitor 2 blocks uptake of uric acid in HEK293 cells expressing URAT1, with a Ki value of 0.145 μM. URAT1&XO inhibitor 2 decreases serum urate level and uric acid excretion in hyperuricemic mice. URAT1&XO inhibitor 2 can be used for research of hyperuricemia.
    URAT1&XO inhibitor 2
  • HY-14669
    Niraxostat
    		Inhibitor 98.54%
    Niraxostat (Y-700; Piraxostat) is an orally active xanthine oxidoreductase (XOR) inhibitor used in the study of hyperuricemia and other diseases in which XOR may be involved.
    Niraxostat
  • HY-W008550
    8-Azaadenine
    		Inhibitor 99.69%
    8-Azaadenine is a Xanthine Oxidase inhibitor (IC50 = 0.54 μM).
    8-Azaadenine
  • HY-19657S
    Oxypurinol-13C,15N2
    		Inhibitor
    Oxypurinol-13C,15N2 is 15N and 13C labeled Oxypurinol (HY-19657). Oxipurinol (Oxipurinol), the major active metabolite of Allopurinol, is an inhibitor of xanthine oxidase. Oxipurinol can be used to regulate blood urate levels and treat gout.
    Oxypurinol-<sub>13</sub>C,<sub>15</sub>N<sub>2</sub>
  • HY-14268A
    Febuxostat sodium
    		Inhibitor
    Febuxostat (TEI 6720) sodium is a potent, selective and non-purine xanthine oxidase (XO) inhibitor with a Ki value of 0.6 nM. Febuxostat sodium has the potential for the research of hyperuricemia and gout.
    Febuxostat sodium
  • HY-147908
    Adenosine receptor inhibitor 2
    Adenosine receptor inhibitor 2 (compound 14b) is a potent AR (adenosine receptor) inhibitor. Adenosine receptor inhibitor 2 shows dual affinity toward A1/A2A ARs with higher affinity for the A1- than the A2AAR. Adenosine receptor inhibitor 2 has Ki values of 52.2 nM for the A1AR and 167 nM for the A2AAR.
    Adenosine receptor inhibitor 2
  • HY-162910
    HDAC-IN-79
    		Inhibitor
    HDAC-IN-79 (compound 4) is an orally active dual xanthine oxidase-HDAC inhibitor (Xanthine oxidase: IC50=6.6 nM; HDAC1: IC50=134 nM; HDAC2: IC50=284 nM; HDAC3: IC50=173 nM; HDAC6: IC50=1.32 nM;), with significant in vivo anti-hyperuricemia and anti-tumor activities. HDAC-IN-79 is the most potent cell growth inhibitor (IC50=0.706 μM) of leukemia HL60 cells, induces apoptosis and autophagy, and can regulate the expression levels of signature biomarkers associated with intracellular HDAC inhibition.
    HDAC-IN-79
Cat. No. Product Name / Synonyms Application Reactivity